11月5日，2002届系友、纽约州立大学Buffalo分校药学院副教授曲峻回系进行学术交流，做了题为“Are we there yet: Large-scale proteomics in clinical and pharmaceutical research” 的学术报告。

个人简介：Dr. Jun Qu's primary appointment is in Pharmaceutical Sciences Department of SUNY-Buffalo. He recieved his Ph.D in Analytical Chemistry at Tsinghua University, Beijing, China, in 2002. His interests are in Proteomics and Pharmaceutical Analysis, and his research programs in the proteomics field involve: i) High-resolution and large-scale expression profiling of pathological proteomes (e.g. for cardiovascular diseases, colon cancer and infectious diseases, HIV, COPD, etc) for the discovery of disease/therapeutic biomarkers by gel-free LC/MS methods; ii) Sensitive identification, localization and quantification of post-translational modifications in complex proteomes, with the emphases on arginine methylation and phosphorylation. Novel anti-PTM-peptides capture procedure and alternating collision induced dissociation (CID)/electron transferring dissociation (ETD) are employed to obtain abundant PTM information; iii) Targeted quantification of regulatory, marker proteins for clinical study. Dr. Qu's lab possesses many state-of-the-art LC/MS instruments, including a high resolution/accuracy Orbitrap Fusion, two highly sensitive TSQ Quantum Ultra EMR triple-quadrupole instrument, two ultra-high pressure nano-LC systems, and several HPLC instruments for pre-fraction and ion chromatography. A number of key analytical advances have been developed by his lab that greatly enhanced the proteomic coverage, sensitivity and throughput for proteomic research. As for the Pharmaceutical Analysis of small-molecule drug/markers, Dr. Qu's lab is focusing on the ultra-sensitive quantifications of drug, metabolites and endogenous markers (e.g. corticosteroids, di-hydroxyl-vitamin D metabolites, androgens, etc.) using a novel combination of selective enrichment and micro- or nano-LC/MS.

个人主页：http://www.acsu.buffalo.edu/~junqu/members_junqu.html